(Q39817102)

14 September 2017

title

The role of heterogeneous nuclear ribonucleoprotein K in the progression of chronic myeloid leukemia (English)

1 reference

ribonucleoprotein complex

14 September 2017

main subject

chronic myeloid leukemia

0 references

1 reference

1 reference

Qingfeng Du

1

1 reference

14 September 2017

Li Wang

2

1 reference

14 September 2017

Hongqian Zhu

3

1 reference

14 September 2017

Song Zhang

4

1 reference

14 September 2017

Lulu Xu

5

1 reference

14 September 2017

Weiyang Zheng

6

1 reference

14 September 2017

Xiaoli Liu

7

1 reference

14 September 2017

publication date

4 August 2009

1 reference

14 September 2017

1 reference

14 September 2017

volume

27

1 reference

14 September 2017

issue

3

1 reference

14 September 2017

page(s)

673-679

1 reference

https://scigraph.springernature.com/pub.10.1007/s12032-009-9267-z

14 September 2017

exact match

0 references

cites work

The Biology of CML blast crisis

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS12032-009-9267-Z

Role of BCR/ABL gene-expression levels in determining the phenotype and imatinib sensitivity of transformed human hematopoietic cells

21 January 2018

1 reference

12 December 2020

Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy.

1 reference

12 December 2020

Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia

1 reference

12 December 2020

Abnormal expression of the programmed cell death 5 gene in acute and chronic myeloid leukemia

1 reference

12 December 2020

BCR-ABL suppresses C/EBPalpha expression through inhibitory action of hnRNP E2.

1 reference

12 December 2020

Membrane depolarization and calcium influx stimulate MEK and MAP kinase via activation of Ras.

1 reference

12 December 2020

c-Src-mediated phosphorylation of hnRNP K drives translational activation of specifically silenced mRNAs

1 reference

12 December 2020

The primary structure of MEK, a protein kinase that phosphorylates the ERK gene product

1 reference

12 December 2020

Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells

1 reference

12 December 2020

The roles of heterogeneous nuclear ribonucleoproteins in tumour development and progression

1 reference

12 December 2020

A MAPK/HNRPK pathway controls BCR/ABL oncogenic potential by regulating MYC mRNA translation

1 reference

12 December 2020

The biology of CML blast crisis

1 reference

12 December 2020

hnRNP K: one protein multiple processes

1 reference

12 December 2020

A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002)

1 reference

12 December 2020

STAT5 signaling is required for the efficient induction and maintenance of CML in mice

1 reference

12 December 2020

Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor

1 reference

12 December 2020

The Jab1/COP9 signalosome subcomplex is a downstream mediator of Bcr-Abl kinase activity and facilitates cell-cycle progression.

1 reference

12 December 2020

Loss of p53 impedes the antileukemic response to BCR-ABL inhibition

1 reference

12 December 2020

Identification of the sites in MAP kinase kinase-1 phosphorylated by p74raf-1

1 reference

12 December 2020

Heterogeneous nuclear ribonucleoprotein K is over expressed, aberrantly localised and is associated with poor prognosis in colorectal cancer

1 reference

12 December 2020

Translational regulation by the p210 BCR/ABL oncoprotein

1 reference

12 December 2020

Overexpression of the heat-shock protein 70 is associated to imatinib resistance in chronic myeloid leukemia

1 reference

12 December 2020

Beyond single pathway inhibition: MEK inhibitors as a platform for the development of pharmacological combinations with synergistic anti-leukemic effects

1 reference

12 December 2020

ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party o

1 reference

12 December 2020

hnRNP K: an HDM2 target and transcriptional coactivator of p53 in response to DNA damage

1 reference

12 December 2020

Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia

1 reference

12 December 2020

Activating mutations of RTK/ras signal transduction pathway in pediatric acute myeloid leukemia

1 reference

12 December 2020

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

1 reference

12 December 2020

Sensitivity to the abl inhibitor STI571 in fresh leukaemic cells obtained from chronic myelogenous leukaemia patients in different stages of disease

1 reference

12 December 2020

hnRNP A1 nucleocytoplasmic shuttling activity is required for normal myelopoiesis and BCR/ABL leukemogenesis

1 reference

12 December 2020

10.1007/S12032-009-9267-Z

Identifiers

DOI

1 reference

14 September 2017

1 reference